Subscribe to Search results

The Caxton Foundation was established by a deed of Trust.

Published on:

Caxton's National Welfare Committee reported that in the first six months of active operation a third of applications were left undecided because more information was needed.

Published on:

Ann Lloyd and Jan Barlow expressed concerns about Caxton's administrative processes, its staff and the communication with beneficiaries.

Published on:

The Department of Health rejected the business case submitted by Caxton for increased funding for 2014/15.

Published on:

The Caxton newsletter provided only very limited information in terms of guidelines or support for which beneficiaries could apply.

Published on:

The Skipton Fund contacted people who had received a Skipton Stage 1 payment, but with whom there had been no subsequent communication. The number of Caxton beneficiaries rose by nearly 60%.

Published on:

The pressure on funds was such that the annual fuel allowance had to be reduced.

Published on:

The APPG Report was critical of the Caxton Foundation.

Published on:

The first Bovine Spongiform Encephalopathy ("BSE", mad cow disease) case was confirmed.

Published on:

BSE was first formally identified as variant Creutzfeldt Jakob Disease ("vCJD") in humans.

Published on:

The probable link between BSE in cows and vCJD in humans was announced in Parliament.

Published on:

Blood transfusion services were required to ask about family history of CJD.

Published on:

The Chief Medical Officer issued a statement reporting that three patients who had suffered from vCJD had been blood donors, and a fourth was suspected of having been one too.

Published on:

The Advisory Committee on the Microbiological Safety of Blood and Tissues for Transplantation agreed that recipients of vCJD-implicated product should not be informed.

Published on:

The National Blood Authority initiated a recall of plasma products after establishing that they contained contributions from a donor who subsequently developed vCJD.

Published on:

The National Blood Authority began working towards the possible extension of leucodepletion of blood.

Published on:

The United Kingdom Haemophilia Centre Directors' Organisation recommended recombinant Factor 8 for Haemophilia A.

Published on:

The Government announced the leucodepletion programme, which was implemented by the National Blood Service over time and completed by October 1999.

Published on:

The Government announced a programme to phase out the use of UK-sourced plasma in the manufacture of blood products.

Published on:

The CJD Incidents Panel was established.

Published on: